Endonovo Therapeutics Bundle
Who Owns Endonovo Therapeutics?
Understanding a company's ownership is key to its strategy and accountability. Endonovo Therapeutics recently spun off its medical device assets, including the SofPulse® line, into a new entity, SofPulse, Inc., in March 2024. This highlights the importance of knowing who influences Endonovo Therapeutics.
Endonovo Therapeutics, a biotech firm focused on non-invasive treatments, was founded to develop wearable devices using bioelectricity for healing. Its primary product, the SofPulse® device, aims to reduce pain and inflammation.
Who owns Endonovo Therapeutics Company?
As of July 27, 2025, Endonovo Therapeutics, Inc. is a public company trading under OTCPK:ENDV, with a market capitalization of approximately US$241.32k. Its trailing 12-month revenue as of March 31, 2025, was $1.66K. This analysis will explore Endonovo Therapeutics' ownership, from its founders and early investors to its current public shareholders and institutional holdings, and how the spin-off of Endonovo Therapeutics BCG Matrix impacts its control and future.
Who Founded Endonovo Therapeutics?
Endonovo Therapeutics, Inc. began its journey in November 2008 as Hanover Asset Management, Inc. Steven Mann, a seasoned professional with extensive experience in mergers, acquisitions, and operational management, acquired the assets of Hanover Asset Management in 2008. Mann was instrumental in guiding the company towards its public listing on the OTCBB in 2012, rebranding it as Endonovo Therapeutics, Inc.
Founding and Early Acquisition
Steven Mann acquired the assets of Hanover Asset Management in 2008, marking the inception of the company that would become Endonovo Therapeutics, Inc. His leadership was crucial in the company's transition to public trading.
Public Listing
Under Steven Mann's direction, the company successfully listed on the OTCBB in 2012. This event signified a major milestone in its early corporate history.
Shift to Biotechnology Focus
In 2013, the company pivoted its strategic direction towards biotechnology. This involved a concentrated effort on developing intellectual property within medical devices and regenerative medicine.
Early Funding Rounds
The company secured initial funding in August 2014. A significant infusion of $5 million occurred in November 2016 from an anonymous strategic investor, specifically targeting the Immunotronics platform.
Strategic Investor Confidence
The $5 million investment in 2016 underscored early confidence in Endonovo's bioelectronic therapies. These funds were earmarked for retiring convertible debt and advancing pre-clinical studies.
Founders' Influence
While precise initial equity splits are not public, Steven Mann's role in asset acquisition and the company's early public listing suggests substantial founding influence. The founding team's vision shaped the early distribution of control.
The early ownership structure of Endonovo Therapeutics, Inc. is primarily shaped by Steven Mann's foundational acquisition and leadership. Although specific shareholding percentages from the company's inception are not publicly detailed, Mann's pivotal role in acquiring the initial assets and orchestrating the 2012 OTCBB listing indicates a significant early stake and control. The company's strategic shift to biotechnology in 2013 and subsequent funding rounds, including a notable $5 million investment from an anonymous strategic investor in November 2016 for its Immunotronics platform, further influenced its ownership landscape. This investment aimed to retire convertible debt and support pre-clinical studies, highlighting external validation of the company's direction. Public records do not indicate any early ownership disputes, vesting schedules, or buy-sell agreements that would alter this foundational ownership narrative. The early distribution of control was guided by the founding team's vision, particularly their focus on non-invasive electroceutical therapies, a strategy that continued to shape the company's trajectory and its Competitors Landscape of Endonovo Therapeutics.
Key Aspects of Early Endonovo Therapeutics Ownership
The initial ownership and control of Endonovo Therapeutics were heavily influenced by its founder, Steven Mann, and early strategic investors. The company's evolution from asset management to a biotechnology focus marked significant shifts in its operational and financial structure.
- Steven Mann acquired the company's predecessor, Hanover Asset Management, Inc., in 2008.
- Mann led the company to its OTCBB listing in 2012 as Endonovo Therapeutics, Inc.
- The company transitioned to a biotechnology focus in 2013.
- An anonymous strategic investor provided $5 million in November 2016 for the Immunotronics platform.
- Early ownership details, such as specific equity splits, are not publicly disclosed.
- No public records of early ownership disputes were found.
Endonovo Therapeutics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Endonovo Therapeutics’s Ownership Changed Over Time?
The ownership structure of Endonovo Therapeutics has evolved significantly since its 2012 OTCBB listing, particularly after its 2013 shift to a biotechnology focus. This strategic change influenced its investor base, leading to a predominantly individual shareholder profile.
| Date | Event | Impact on Ownership |
|---|---|---|
| 2012 | Listed on OTCBB | Established initial public ownership |
| 2013 | Transitioned to biotechnology focus | Shifted investor profile |
| December 2022 | Announced spin-off of medical device assets | Initiated corporate restructuring affecting ownership |
| March 2023 | Signed Letter of Intent for spin-off | Formalized separation plan |
| March 2024 | Finalized Asset Purchase Agreement for spin-off | Completed asset transfer, creating new ownership entity |
As of March 31, 2025, institutional ownership in Endonovo Therapeutics was reported at a minimal 0.00%, with Family CFO Inc. being the sole institutional holder at that time, though they have since divested their position. This suggests that the majority of Endonovo Therapeutics stock is held by individual investors. A pivotal development in the company's structure was the spin-off of its medical device division, including the SofPulse® line, into a new entity, SofPulse, Inc. This transaction, finalized in March 2024 for a minimum of $50 million, effectively divided the company's assets and, consequently, its ownership interests. SofPulse, Inc., under the leadership of Ira Weisberg, now concentrates on the commercialization of these medical devices, while Endonovo Therapeutics retains rights to non-medical human PEMF intellectual property and the wellness market. This strategic maneuver has led to a substantial increase in shares outstanding; as of July 14, 2025, Endonovo Therapeutics had 1.1 billion shares outstanding, a significant rise from the 396,827,945 common shares recorded on June 30, 2024, and further increasing to 1,097,921,313 by March 14, 2025, indicating considerable shareholder dilution over the past year. Understanding these shifts is crucial for anyone looking into Endonovo Therapeutics ownership and who owns Endonovo Therapeutics company.
Key Ownership Developments
The ownership of Endonovo Therapeutics has been shaped by strategic asset spin-offs and a shift towards individual investors.
- Institutional ownership is currently 0.00% as of March 31, 2025.
- A significant spin-off of medical device assets occurred in March 2024.
- Shares outstanding increased from approximately 397 million in June 2024 to over 1.1 billion by July 2025.
- The company's focus has evolved, impacting its investor base and corporate structure.
- For a deeper understanding of strategic shifts, explore the Growth Strategy of Endonovo Therapeutics.
Endonovo Therapeutics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Endonovo Therapeutics’s Board?
As of June 30, 2024, Endonovo Therapeutics, Inc. operates with a highly centralized leadership structure, featuring Andre' DiMino as the sole executive officer and director, holding the key roles of President, Chief Executive Officer, and Chief Financial Officer.
| Position | Name | Key Responsibilities |
|---|---|---|
| President, CEO, CFO | Andre' DiMino | Overall company leadership, financial management, strategic direction |
The voting power within Endonovo Therapeutics is significantly influenced by its Series AA Super Voting Preferred Stock. Each share of this preferred stock carries 100,000 votes, a structure designed to ensure that management maintains control over director elections and that common stockholders do not gain majority control, even after public offerings. As of December 31, 2023, and December 31, 2022, there were 25,000 shares of Series AA Preferred Stock outstanding, consolidating substantial voting power with a select group of shareholders. This arrangement inherently limits the influence of common shareholders on governance decisions, potentially reducing the likelihood of typical activist investor campaigns impacting the company's direction.
Understanding Endonovo Therapeutics' Voting Power
Endonovo Therapeutics' corporate governance is heavily weighted towards its preferred stockholders. This structure ensures a stable leadership and limits the influence of common shareholders.
- Series AA Super Voting Preferred Stock grants 100,000 votes per share.
- This structure prevents common stockholders from gaining majority control.
- Andre' DiMino holds all executive and director positions as of June 30, 2024.
- The company's ownership structure is designed for concentrated control.
- Understanding this is key to grasping Revenue Streams & Business Model of Endonovo Therapeutics.
Endonovo Therapeutics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Endonovo Therapeutics’s Ownership Landscape?
Endonovo Therapeutics has undergone significant ownership shifts in recent years, largely due to a strategic spin-off of its medical device division. This move aimed to streamline operations and enhance shareholder value by separating distinct business segments.
| Event | Date | Details |
|---|---|---|
| Medical Device Spin-off Announced | December 2022 | Spin-off of medical device assets, including SofPulse®, to SofPulse, Inc. |
| Asset Purchase Agreement Finalized | March 2024 | Minimum of $50 million for medical device assets. |
| Common Shares Outstanding | June 30, 2024 | 396,827,945 |
| Common Shares Outstanding | July 14, 2025 | 1.1 billion |
The spin-off of its medical device assets, including the SofPulse® product line, to a newly formed entity, SofPulse, Inc., finalized in March 2024 for a minimum of $50 million, represents a pivotal moment in Endonovo Therapeutics' ownership trajectory. SofPulse, Inc. is now positioned for potential growth, with plans for a NASDAQ listing and projected sales exceeding $100 million by 2024. Endonovo Therapeutics, Inc. retains exclusive rights to non-medical human PEMF intellectual property and wellness markets. This strategic unbundling aligns with industry trends focused on operational efficiency and value unlocking. The company is also developing a telehealth division to create new revenue streams and reduce costs. Shareholder dilution has been substantial, with common shares outstanding increasing from approximately 396.8 million in June 2024 to 1.1 billion by July 2025. Despite a general market trend away from shareholder activism towards value and capital allocation in the 2025 proxy season, Endonovo's dual-class share structure, featuring super-voting preferred stock, offers robust protection against activist campaigns. Information regarding succession plans for its sole executive officer and director, Andre' DiMino, or further privatization or public listing plans for Endonovo Therapeutics itself, beyond the SofPulse, Inc. spin-off, has not been publicly disclosed.
SofPulse, Inc. Spin-off
The separation of medical device assets into SofPulse, Inc. aims to create a more focused entity. This strategic move is expected to unlock value for shareholders of both companies.
Ownership Structure and Dilution
Significant share dilution has occurred, increasing the number of common shares outstanding. The company's dual-class share structure provides a defense against activist investors.
Future Business Development
Endonovo Therapeutics is exploring a telehealth division to diversify revenue. The company retains rights to non-medical human PEMF intellectual property and wellness markets.
Management and Governance
Current leadership consists of a sole executive officer and director. No public statements have been made regarding succession plans or future listing strategies for Endonovo Therapeutics.
Endonovo Therapeutics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Endonovo Therapeutics Company?
- What is Competitive Landscape of Endonovo Therapeutics Company?
- What is Growth Strategy and Future Prospects of Endonovo Therapeutics Company?
- How Does Endonovo Therapeutics Company Work?
- What is Sales and Marketing Strategy of Endonovo Therapeutics Company?
- What are Mission Vision & Core Values of Endonovo Therapeutics Company?
- What is Customer Demographics and Target Market of Endonovo Therapeutics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.